Quantcast
Last updated on April 20, 2014 at 19:30 EDT

Latest Avastin Stories

2008-07-01 06:00:49

SAN DIEGO, July 1 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. today announced preliminary response rate results from its discontinued Phase 3 clinical trial of ANX-510, or CoFactor, the Company's folate-based biomodulator of 5-FU (5 fluorouracil), for the treatment of first-line metastatic colorectal cancer. The primary endpoint of the study was progression-free survival, which is expected to mature and be reported by the Company along with safety data later this year. Data...

2007-01-23 15:00:58

Preliminary results show the combination of Xeloda plus Eloxatin, known as XELOX, to be equivalent to standard FOLFOX-4 chemotherapy treatment in terms of overall survival in first-line metastatic colorectal cancer patients. Given its dosing convenience advantage, XELOX has the potential to be a first-line treatment, provided it can be demonstrated as cost-effective. The 2,034 metastatic colorectal cancer patient study was originally designed to compare first-line XELOX (Roche/Chugai's...

2006-08-21 03:00:43

LONDON (Reuters) - Two new targeted therapies for bowel cancer should not be used on Britain's state-run health service, the country's cost-effectiveness watchdog NICE said on Monday. The recommendation angered patient groups, since both Avastin and Erbitux are widely available in the United States and much of Europe. The National Institute for Health and Clinical Excellence (NICE), however, decided the high cost of the medicines meant their use was not "compatible with the best use...

2006-06-05 13:15:42

LOS ANGELES (Reuters) - A mid-stage trial suggests that a combination of cancer drugs Avastin and Tarceva can prolong survival in patients with advanced lung cancer, compared with chemotherapy alone, drug makers Genentech Inc. and OSI Pharmaceuticals said on Monday Avastin, made by Genentech, is the first cancer drug designed to work by cutting off blood supply to tumors. Tarceva, a product of Genentech and OSI, is an oral drug designed to target the human epidermal growth factor...

2006-04-12 01:23:47

ZURICH (Reuters) - Switzerland's Roche has filed for approval in the United States its Avastin cancer drug for treatment of the most widespread form of lung cancer, the drug-maker said on Wednesday. Studies had shown that Avastin was beneficial to patients suffering from non-squamous non-small cell lung cancer -- which accounts for 87 percent of all lung cancer cases in the United States -- in combination with chemotherapy. "Avastin is the first and only treatment in more than a...

2006-03-22 08:33:20

LONDON (Reuters) - Combining the drug Avastin with standard chemotherapy can keep breast cancer under control for longer in patients with advanced disease, scientists said on Wednesday. Avastin, which is made by Roche Holding AG and its majority-owned U.S. biotech arm Genentech Inc, blocks the growth of new blood vessels that are needed for the cancer to grow and spread, or metastasize, beyond the breast. When doctors combined the drug with the chemotherapy treatment Taxol in a study...

2005-10-19 07:19:29

CHICAGO (Reuters) - Genentech Inc. said on Tuesday early results from a mid-stage trial show that combining lung cancer drug Tarceva with Avastin works no better than Avastin alone in patients with advanced kidney cancer, sending shares of Tarceva partner OSI Pharmaceuticals Inc. down 7 percent. As a result, the world's No. 2 biotechnology company said it will not pursue further studies of the Avastin/Tarceva combination in kidney cancer but will continue to analyze the results of...

2004-11-30 00:00:24

Nov. 30--Genentech's cancer drug Avastin helped boost survival for patients with colorectal cancer by two months, researchers announced Monday. While the gains in median survival were modest, the large-scale study sponsored by the National Cancer Institute underscores the effectiveness of the drug in prolonging the lives of some of the sickest patients with one of the deadliest forms of cancer. The new findings could boost sales of Avastin, which reached $183 million for the...

1f81ecc5ad08acab842b7a7fd3089a5e1
2004-11-29 15:00:00

SAN FRANCISCO -- Genentech Inc. said Monday its novel colon cancer-fighting drug Avastin helped some of the sickest patients stay alive two months longer than expected, giving the drug an additional boost on its way to blockbuster status. The South San Francisco-based biotechnology titan made the announcement ahead of a major conference for cancer researchers and doctors scheduled for January, when the company said it would release more detailed results from a large-scale human experiment...

2004-11-29 12:00:19

SOUTH SAN FRANCISCO, Calif. and BASEL, Switzerland, Nov. 29 /PRNewswire-FirstCall/ -- Genentech, Inc. and Roche (SWX Zurich) today announced that a randomized Phase III study of Avastin(TM) (bevacizumab) plus the FOLFOX4 chemotherapy regimen (oxaliplatin/5-FU/leucovorin), compared to FOLFOX4 alone, in second-line metastatic colorectal cancer patients achieved its primary endpoint of improving overall survival. Results from an interim analysis demonstrated that patients receiving Avastin...